WHO ICTRP trial
Gabapentin for taxane associated acute pain syndrome - randomised…
ACTRN12611000666921 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12611000666921 |
|---|---|
| Public title | Gabapentin for taxane associated acute pain syndrome - randomised, placebo-controlled, crossover trial. The TAPS Trial |
| Scientific title | In patients receiving docetaxel for early stage breast cancer who experience taxane associated acute pain syndrome is gabapentin better than placebo for reducing pain? |
| Primary sponsor | Sunshine Coast Cancer Centre, Nambour General Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia |
| Conditions | Breast cancer;Taxane associated acute pain syndrome; Breast cancer Taxane associated acute pain syndrome;Cancer - Breast |
| Interventions | Gabapentin 300mg three times a day, orally. Starting the day before chemotherapy, for 6 days in total. The chemotherapy is given every three weeks thus there will be a three week wash out period between the intervention and placebo arms… |
| Registration date | Jan 7, 2011 |
| Target size | 126 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: